Sistema de Salut de Catalunya
Institut Català de la Salut
[Zabalza A, Pappolla A, Comabella M, Malhotra S] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Montalban X] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Faculty of Medicine, University of Vic - Central University of Catalonia (UVicUCC), Vic, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-10-30T07:00:42Z
2024-10-30T07:00:42Z
2024-08-29
Biomarkers; MicroRNAs; Multiple sclerosis
Biomarcadors; MicroRNAs; Esclerosi múltiple
Biomarcadores; MicroRNAs; Esclerosis múltiple
This review will briefly introduce microRNAs (miRNAs) and dissect their contribution to multiple sclerosis (MS) and its clinical outcomes. For this purpose, we provide a concise overview of the present knowledge of MS pathophysiology, biomarkers and treatment options, delving into the role of selectively expressed miRNAs in clinical forms of this disease, as measured in several biofluids such as serum, plasma or cerebrospinal fluid (CSF). Additionally, up-to-date information on current strategies applied to miRNA-based therapeutics will be provided, including miRNA restoration therapy (lentivirus expressing a specific type of miRNA and miRNA mimic) and miRNA inhibition therapy such as antisense oligonucleotides, small molecules inhibitors, locked nucleic acids (LNAs), anti-miRNAs, and antagomirs. Finally, it will highlight future directions and potential limitations associated with their application in MS therapy, emphasizing the need for improved delivery methods and validation of therapeutic efficacy
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SM was supported by the grant from Instituto Salud Carlos III (PI20/01697) and cofunded by the European Union.
Article
Published version
English
Teràpia genètica; Esclerosi múltiple - Tractament; MicroARN; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis; Other subheadings::Other subheadings::/therapy; CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Genetic Therapy; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple; Otros calificadores::Otros calificadores::/terapia; COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::terapia genética
Frontiers Media
Frontiers in Immunology;15
https://doi.org/10.3389/fimmu.2024.1441733
info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01697
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - CEMCAT [136]
Articles científics - HVH [3396]
